Tunitas Therapeutics is a biopharmaceutical company developing targeted protein therapeutics designed to change the lives of allergy sufferers. With Tunitas proteins, patients receive a treatment regimen in their allergists office designed to alter the natural course of their disease, providing a therapeutic option with long-lasting benefit. The firm's proprietary platform facilitates the generation of fusion proteins that target novel inhibitory pathways on allergic cells, leading to inhibition of the key mediators of allergic hypersensitivity and the production of IgE, the antibody class that triggers the allergic response. Epsi-gam, the companys lead drug candidate, is designed as a long-term treatment for any IgE-mediated disease, including asthma and severe food allergy. The molecule has recently entered phase 1 clinical trials. Specific treatments for cat allergy and peanut allergy will follow epsi-gam into the clinic.
